September 18, 2020 -- Elicio Therapeutics and the Moffitt Cancer Center have established a collaboration to study Elicio's amphiphile immunotherapies with CD19 chimeric antigen receptor (CAR) T cells.
The study will explore the combination of Elicio's AMP-CD19 with CD19 CAR T cells to treat lymphomas and other B-cell malignancies. AMP-CD19 is a CAR-binding peptide that is modified to traffic into lymph nodes for display on native immune cells.
AMP-CD19 can activate engineered T cells to enhance their persistence and proliferation, as well as increase activity against B-cell malignancies such as diffuse large B-cell lymphoma and acute lymphocytic leukemia.
The research will be led by Dr. Marco Davila, PhD, associate member of the blood and marrow transplant and cellular immunotherapies department and medical director of cell therapies at Moffitt.